Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response-adapted Toripalimab for Locally Advanced Nasopharyngeal Carcinoma
NCT05628922Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jul 2022
- Primary completion
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in nasopharyngeal carcinoma (NPC), sponsored by Fudan University. Started Jul 2022; status: recruiting.
02
Drugs
toripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05628922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05628922.